title: Effect of Cystone® on urinary composition and stone formation over a one year period.
abstract: Kidney stones are a common problem for which inadequate prevention exists. We recruited ten recurrent kidney stone formers with documented calcium oxalate stones into a two phased study to assess safety and effectiveness of Cystone(®), an herbal treatment for prevention of kidney stones. The first phase was a randomized double-blinded 12 week cross over study assessing the effect of Cystone(®) vs. placebo on urinary supersaturation. The second phase was an open label one year study of Cystone(®) to determine if renal stone burden decreased, as assessed by quantitative and subjective assessment of CT. Results revealed no statistically significant effect of Cystone(®) on urinary composition short (6 weeks) or long (52 weeks) term. Average renal stone burden increased rather than decreased on Cystone(®). Therefore, this study does not support the efficacy of Cystone(®) to treat calcium oxalate stone formers. Future studies will be needed to assess effects on stone passage, or on other stone types.
authors.affiliation: Division of Nephrology & Hypertension, Ma-E19, Mayo Clinic, Rochester, MN 55905, USA. erickson.stephen@mayo.edu
authors.forename: S B
authors.initials: SB
authors.lastname: Erickson
authors.forename: T J
authors.initials: TJ
authors.lastname: Vrtiska
authors.forename: J C
authors.initials: JC
authors.lastname: Lieske
mesh_terms: D000328:Adult; D000368:Aged; D002129:Calcium Oxalate / Q000378:metabolism*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology*; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome; D014556:Urine / Q000737:chemistry*
chemical_list: D010919:Placebos; D010936:Plant Extracts; C041060:cystone; D002129:Calcium Oxalate